New IMB Publication

Artur Fassoni (02/2017 – 02/2018 guest scientist at the IMB), Christoph Baldow, Ingo Röder and Ingmar Glauche (all IMB) published a paper in the November 2018 Issue of „Haematologica“, which is the official Journal of the European Hematology Association (EHA). This work  addresses a model-based prediction of tyrosine kinase inhibitor (TKI) – doses in the treatment of patients with chronic myeloid leukaemia (CML) (http://www.haematologica.org/content/103/11/1825).

The central result of the publication is the theoretical prediction that TKI dose de-escalation is a potential therapeutic option for many CML patients. As highlighted in an editorial article of this „Haematologica“ issue  (http://www.haematologica.org/content/103/11/1756), the paper illustrates the potential benefit of the application of mathematical models in the context of treatment optimization and individualization using a concrete and highly relevant example. If the presented theoretical predictions can be confirmed in clinical trials, this could lead to a significant reduction of treatment-related side effects as well as to cost reductions without losing treatment efficiency.